Cambridge, UK. 7 April 2005 CellCentric, a leading company in the exploitation of epigenetics, announces that it has received new funding of £250,000 from the Rainbow Seed Fund, complementing initial investments from Avlar BioVentures and Providence Investment Co. Ltd. This investment has enabled a new commercial relationship with the Babraham Institute, Cambridge, one of Europe’s leading centres of excellence in epigenetic research.
